Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FluPRINT

Financiado

Cerrado

Tracing the inFLUenza vaccine imPRINT on immune system to identify cellular sign...

Tracing the inFLUenza vaccine imPRINT on immune system to identify cellular signature of protection Influenza virus causes a large socioeconomic burden on society, with 70 000 deaths every year in Europe. It is estimated that 1 in 1000 children and elderly every year are hospitalized due to influenza infection. Children, due to... ver más

31/05/2021

UOXF

270K€

Presupuesto del proyecto: 270K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-05-31

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UOXF

269.86K€ | Lider

BOARD OF TRUSTEES OF THE LEL...

STANFORD

172.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IRINVAC IMMUNE RESPONSES TO INFLUENZA VACCINE 100K€ Cerrado

EDUFLUVAC Combinatorial immunization strategy to educate the immune sy... 6M€ Cerrado

RTI2018-094213-A-I00 PAPEL DE PROTEINAS DEL VIRUS DE LA GRIPE EN LA INDUCCION DE... 121K€ Cerrado

FLUCOP Standardization and Development of Assays for Assessment of... 14M€ Cerrado

IMECS Identification of Mechanisms Correlating with Susceptibility... 4M€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2018-04-12
Fecha Fin: 2021-05-31

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 270K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Influenza virus causes a large socioeconomic burden on society, with 70 000 deaths every year in Europe. It is estimated that 1 in 1000 children and elderly every year are hospitalized due to influenza infection. Children, due to high susceptibility and high levels of shedding, are the main source of spread of the virus. Therefore, CDC in 2010 included children as a high priority group for influenza vaccination. Two influenza vaccines are licensed: inactivated (IIV) and live attenuated (LAIV) vaccine. The LAIV was introduced to provide broader protection by additional stimulation of T cell responses. At present the two major obstacles in the widespread use of LAIV are concerns raised over vaccine effectiveness and the lack of immunological correlates of protection. In 2016 the CDC in the US recommended against the use of LAIV due to its poor effectiveness in the 2015/2016 season. However, the same vaccine, in the same season had high effectiveness as assessed by UK and Finland public health authorities. Currently the reason for this discrepancy is not known. This project will take advantage of cohorts of children who have received LAIV provided by both US and UK sponsors, to investigate the immunological basis for the observed variability and to define the role of adaptive immunity by applying the systems biology tools and machine learning algorithms for predictive modelling. Progress in the clinical investigation of children has been hampered by limited methods that could be applied to the small blood volumes, but recent advances in systems biology have opened new opportunities that did not exist before. Tracing the influenza vaccine imprint on immune system, termed FluPRINT by the proposed project will help to identify cellular signatures of vaccine-induced protection in children which is of importance for the development of next generation of influenza vaccines that will be more effective in this target population.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores